These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
692 related articles for article (PubMed ID: 18404164)
1. The ERBB3 receptor in cancer and cancer gene therapy. Sithanandam G; Anderson LM Cancer Gene Ther; 2008 Jul; 15(7):413-48. PubMed ID: 18404164 [TBL] [Abstract][Full Text] [Related]
2. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Ma J; Lyu H; Huang J; Liu B Mol Cancer; 2014 May; 13():105. PubMed ID: 24886126 [TBL] [Abstract][Full Text] [Related]
3. Role of erbB3 receptors in cancer therapeutic resistance. Lee Y; Ma J; Lyu H; Huang J; Kim A; Liu B Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):190-8. PubMed ID: 24449784 [TBL] [Abstract][Full Text] [Related]
4. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604 [TBL] [Abstract][Full Text] [Related]
5. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Shi F; Telesco SE; Liu Y; Radhakrishnan R; Lemmon MA Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7692-7. PubMed ID: 20351256 [TBL] [Abstract][Full Text] [Related]
6. P2Y2 nucleotide receptors mediate metalloprotease-dependent phosphorylation of epidermal growth factor receptor and ErbB3 in human salivary gland cells. Ratchford AM; Baker OJ; Camden JM; Rikka S; Petris MJ; Seye CI; Erb L; Weisman GA J Biol Chem; 2010 Mar; 285(10):7545-55. PubMed ID: 20064929 [TBL] [Abstract][Full Text] [Related]
7. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047 [TBL] [Abstract][Full Text] [Related]
8. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation. Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617 [TBL] [Abstract][Full Text] [Related]
9. Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain. Thompson M; Lauderdale S; Webster MJ; Chong VZ; McClintock B; Saunders R; Weickert CS Brain Res; 2007 Mar; 1139():95-109. PubMed ID: 17280647 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia. Black LE; Longo JF; Carroll SL Am J Pathol; 2019 Oct; 189(10):1898-1912. PubMed ID: 31351986 [TBL] [Abstract][Full Text] [Related]
11. Oncogenic ERBB3 mutations in human cancers. Jaiswal BS; Kljavin NM; Stawiski EW; Chan E; Parikh C; Durinck S; Chaudhuri S; Pujara K; Guillory J; Edgar KA; Janakiraman V; Scholz RP; Bowman KK; Lorenzo M; Li H; Wu J; Yuan W; Peters BA; Kan Z; Stinson J; Mak M; Modrusan Z; Eigenbrot C; Firestein R; Stern HM; Rajalingam K; Schaefer G; Merchant MA; Sliwkowski MX; de Sauvage FJ; Seshagiri S Cancer Cell; 2013 May; 23(5):603-17. PubMed ID: 23680147 [TBL] [Abstract][Full Text] [Related]
12. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492 [TBL] [Abstract][Full Text] [Related]
13. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Liles JS; Arnoletti JP; Tzeng CW; Howard JH; Kossenkov AV; Kulesza P; Heslin MJ; Frolov A Cancer Biol Ther; 2010 Sep; 10(6):555-63. PubMed ID: 20647770 [TBL] [Abstract][Full Text] [Related]
14. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance. Chen Y; Lu A; Hu Z; Li J; Lu J Cancer Lett; 2024 Sep; 599():217146. PubMed ID: 39098760 [TBL] [Abstract][Full Text] [Related]
15. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells. Yarar D; Lahdenranta J; Kubasek W; Nielsen UB; MacBeath G Mol Cancer Ther; 2015 Sep; 14(9):2072-80. PubMed ID: 26116360 [TBL] [Abstract][Full Text] [Related]
16. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Zhang Y; Linn D; Liu Z; Melamed J; Tavora F; Young CY; Burger AM; Hamburger AW Mol Cancer Ther; 2008 Oct; 7(10):3176-86. PubMed ID: 18852121 [TBL] [Abstract][Full Text] [Related]
17. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Ueno Y; Sakurai H; Tsunoda S; Choo MK; Matsuo M; Koizumi K; Saiki I Int J Cancer; 2008 Jul; 123(2):340-347. PubMed ID: 18398842 [TBL] [Abstract][Full Text] [Related]
19. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. Macdonald-Obermann JL; Adak S; Landgraf R; Piwnica-Worms D; Pike LJ J Biol Chem; 2013 Oct; 288(42):30773-30784. PubMed ID: 24014028 [TBL] [Abstract][Full Text] [Related]
20. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]